ArticleNature communications2021
Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 12 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 12 pooled it
11.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 12 syntheses or guidelines pooled it, 192 citations in OpenAlex.
- Roles of Oxidative Injury and Nitric Oxide System Derangements in Kawasaki Disease Pathogenesis: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- The association between stroke and COVID-19-related mortality: a systematic review and meta-analysis based on adjusted effect estimates.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Pooled it
- Association of statin and/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study.Diabetes & metabolic syndrome · 2022 · on this mapPooled it
- The Association Between the Use of Statins and Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022Pooled it
- Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials.Frontiers in medicine · 2022Pooled it
- The use of statins was associated with reduced COVID-19 mortality: a systematic review and meta-analysis.Annals of medicine · 2021 · on this mapPooled it
- Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies.Diabetes & metabolism · 2021 · on this mapPooled it
- Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147 824 patients.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity.BMC public health · 2021Pooled it
- Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2021 · on this mapPooled it
- The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Improved COVID-19 Outcomes following Statin Therapy: An Updated Systematic Review and Meta-analysis.BioMed research international · 2021Pooled it
- Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial.Respiratory research · 2024Trial
- Trial
- Survival of the hospitalized patients with COVID-19 receiving atorvastatin: A randomized clinical trial.Journal of medical virology · 2022Trial
- Drug Repurposing as a Broad-Spectrum Strategy Against Coronaviruses: Frontiers in Mechanisms and Clinical Translation.Viruses · 2026Review
- The Selective DHCR24 Blocker SH42 Inhibits ACE2 Binding and Cellular Entry of SARS-CoV-2 Spike Proteins More Efficiently Than Atorvastatin.Research (Washington, D.C.) · 2026Article
- Artificial Intelligence in Pharmaceutical Drug Development: Transforming Formulation and Innovation.Current drug discovery technologies · 2026Review
- Household exposure, demographic and health characteristics associated with SARS-CoV-2 infection in a cohort study in Northern France.Scientific reports · 2025Article
- Do Statins Affect Viral Infections Encountered by International Travelers?Tropical medicine and infectious disease · 2025Review
48 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
29 authors at 3 institutions in 2 countries.
Aakriti Gupta *NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA. ag3786@cumc.columbia.edu.ORCID 0000-0001-9103-9872
Mahesh V Madhavan *NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-7740-1481
Timothy J PoteruchaNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Ersilia M DeFilippisNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Jessica A HennesseyNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Bjorn RedforsNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Christina EckhardtNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Behnood BikdeliNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Jonathan PlattNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Ani NalbandianNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-5615-7328
Pierre EliasNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-9643-3024
Matthew J CummingsNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Shayan N NouriNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Matthew LawlorNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Lauren S RanardNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-2305-156X
Jianhua LiNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Claudia BoyleNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Raymond GivensNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Daniel BrodieNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-0813-3145
Harlan M KrumholzYale Center for Outcomes Research and Evaluation, New Haven, CT, USA.ORCID 0000-0003-2046-127X
Gregg W StoneCardiovascular Research Foundation, New York, NY, USA.
Sanjum S SethiNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Daniel BurkhoffNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Nir UrielNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Allan SchwartzNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Martin B LeonNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Ajay J KirtaneNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Elaine Y WanNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA. eyw2003@cumc.columbia.edu.ORCID 0000-0002-5328-7282
Sahil A ParikhNewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-0551-5885
NewYork–Presbyterian Hospital · USCardiovascular Institute of the South · USYale New Haven Hospital · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MNCATS NIH HHS UL1 TR001863
Abstract
The coronavirus disease 2019 (COVID-19) can result in a hyperinflammatory state, leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic complications, among other sequelae. Statins, which are known to have anti-inflammatory and antithrombotic properties, have been studied in the setting of other viral infections, but their benefit has not been assessed in COVID-19. This is a retrospective analysis of patients admitted with COVID-19 from February 1
Indexed as
COVID-19 Drug TreatmentAgedCOVID-19FemaleHospitalizationHospital MortalityHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLogistic ModelsMaleMiddle AgedNew York CityPropensity ScoreRetrospective StudiesSARS-CoV-2Hydroxymethylglutaryl-CoA Reductase Inhibitors
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.